SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsSpeculating in Takeover Targets


Previous 10 Next 10 
From: richardred6/14/2019 1:41:51 PM
   of 6544
 
Sold out earlier-Starting a position in ECA today on the new low.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: richardred6/17/2019 8:42:21 AM
   of 6544
 
Pfizer bolsters cancer portfolio with $10.64 billion deal for Array

(Reuters) - Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash to beef up its cancer portfolio as it faces rising generic competition for its blockbuster drugs.

reuters.com

P.S. Remembering big Pharma at work.

Share RecommendKeepReplyMark as Last Read


From: richardred6/18/2019 1:34:42 PM
   of 6544
 
Up to the Task in an up market with a seemingly depressed stock. Added to $CTG today- looks cheap based on forward earnings. VIA- last few recent bolt acquisitions- European business could be a up and coming bright spot moving forward IMO .

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: richardred6/19/2019 10:06:28 AM
   of 6544
 
Axalta Coating Systems says exploring potential sale of company

(Reuters) - Axalta Coating Systems Ltd initiated a review of strategic options, including a potential sale of the company, the coatings producer said on Wednesday.

Axalta’s market cap was $6.06 billion as of Tuesday’s close, according to IBES data from Refinitiv.

The company said it has hired Evercore and Barclays as financial advisers to assist in the review.

reuters.com

P.S. Oldie's
Akzo Nobel Confirms $30B Merger Talks With Axalta
investopedia.com

Nippon Paint makes proposal to Axalta, merger talks with Akzo Nobel end
reuters.com

https://twitter.com/WSJ

Street Journal ? @WSJ


Akzo Nobel rejects $22 billion offer from PPG t.co

3:20 AM - Mar 9, 2017

PPG Makes $22 Billion Offer for Paint Rival Akzo Nobel, Is Rejected Dutch paints-and-chemicals maker Akzo Nobel said it rejected an unsolicited $22.1 billion offer from U.S. peer PPG, setting up a trans-Atlantic standoff that pits two of the world’s oldest industrial...

wsj.com



Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (5289)6/19/2019 10:40:08 AM
From: richardred
   of 6544
 
AXTA- New Buy- I made a bet that a third time will be a charm. Hypothetically IMO- mid thirties takes it. That's 15% from here. The reason why I bought. Past three Qtrs. of earnings beats. Previous suitors for the company.

Oldie Snip from previous post>Axalta, whose largest shareholder is Warren Buffett’s Berkshire Hathaway Inc, said it continued to pursue other “value-creating alternatives” although it did not disclose Nippon Paint’s role, if any, in the termination of the discussions.

Nippon Paint, Japan’s biggest paint supplier and 39 percent owned by Singapore-based investment company Wuthelam Holdings Ltd, made the all-cash offer at a premium to where Axalta shares ended on Monday at $33.54, one of the sources said. The offer was credible enough for Axalta to end negotiations with Akzo Nobel, the source added.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: E_K_S6/19/2019 2:09:24 PM
   of 6544
 
Investment Bankers making more money . .

GlaxoSmithKline selling consumer portfolios, raising $1.3B
Jun. 19, 2019 2:07 PM ET|About: GlaxoSmithKline plc (GSK)|By: Brandy Betz, SA News Editor

GlaxoSmithKline ( GSK +1.3%) starts selling some consumer health brands in its bid to raise about $1.26B before spinning off the consumer business.

Earlier this week, GSK sent out information packages for two portfolios containing Latin America drugs and Physiogel skin care products, according to Reuters sources.

A third, higher-priced portfolio with European drugs will be sent out after the summer ends and already has PE firm interest.

Investment bank Greenhill is marketing the portfolios to separate bidders.

GSK plans to fold its remaining consumer health business into a JV with Pfizer later this year

Share RecommendKeepReplyMark as Last Read


To: E_K_S who wrote (5261)6/20/2019 9:55:12 AM
From: richardred
   of 6544
 
RE-FCX The company has moved up smartly since.

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (5286)6/20/2019 11:08:35 AM
From: richardred
   of 6544
 
Sold out ECA position. Nice gain in a quick time. Dry powder for later.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (5137)6/20/2019 11:15:49 AM
From: richardred
   of 6544
 
RE-MEI- #4 2019 SITT- Weak earnings-looking for a re-entry at some point in stock price weakness, if it happens.

Share RecommendKeepReplyMark as Last Read


From: richardred6/20/2019 11:56:05 AM
1 Recommendation   of 6544
 
Added some SFM-Sprouts and a new buy of UNFI - UNITED NATURAL FOODS today. Both bargains compared to -

GROCERY OUTLET HOLDING CORPORATION 30.80 8.80 (40.00 %)

Share RecommendKeepReplyMark as Last ReadRead Replies (2)
Previous 10 Next 10